Industry news

• The FMBA has applied for registration of the MIR-19 drug against coronavirus

  19 October 2021 GxPnews

  The State Research Center Institute of Immunology of the Federal Medical and Biological Agency (FMBA) has submitted an application for the registration of MIR-19 drug. The entry in the state register of medicines appeared on October 14.

• ARPU supported the study of the effect that the quality of the drug coating on coronary stents has on their effectiveness

  18 October 2021 GxPnews

  The All-Russian Patient Union (ARPU) supported the initiative of specialists  of the FSBRI Central Clinical Hospital of the Russian Academy of Sciences to form an expert group in order to draw up a research-to-practice protocol to study the effect of the uniformity and stability of the bioresorbable drug coating on coronary stents on the clinical effectiveness of immediate and long-term results. This was reported by the press service of the organization.

• The Ministry of Health approved the development of a gene therapy for cancer with a non-viral delivery system

  18 October 2021 GxPnews

  The Ministry of Health of the Russian Federation has authorized the conduct of phase 1 clinical trials of AntioncoRAN-M (produced at the facilities of the Gamalei Center) for cancer gene therapy with a non-viral delivery system. This is evidenced by the data of the state register of medicines (GRLS) of the department.

• Barriers exist, but participation urgent in breast cancer clinical trials: report

  14 October 2021 FiercePharma

  Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org. 

• The EAEC is developing a plan to increase the provision of the EAEU states with strategically important drugs

  14 October 2021 GxPnews

  The Eurasian Economic Commission (EEC) is developing an action plan to increase the level of provision of the states of the Eurasian Economic Union (EAEU) with strategically important medicines and pharmaceutical substances for medical use, the production of which has to be established in the EAEU by 2024. This was announced by Artak Kamalyan, the Minister of Industry and Agro-Industrial Complex of the Commission, during a visit to Biocad’s research and production center.

• Smart use of off-patent medicines critical for post-COVID healthcare

  13 October 2021 Anna Begley / European Pharmaceutical Review

  Healthcare experts at the Medicines for Europe-International Generic and Biosimilar Association (IGBA) annual conference, held in Athens, Greece, have stated that the smart use of off-patent medicines will be crucial to rebuild healthcare systems successfully post-COVID-19.

• A committee on oncological diseases in HIV-infected patients has been established in Russia

  13 October 2021 GxPnews

  The Association of Russian Oncologists (AOR) has created a special committee dealing with the problems of cancer patients with HIV infection, the press service of the National Medical Research Center (NMRC) of Radiology of the Ministry of Health of the Russian Federation reports.

• Revolutionary biomass-based plastic used for blister packaging

  12 October 2021 Anna Begley / European Pharmaceutical Review

  The blister package is made of biomass-based plastic, polyethylene derived from sugarcane, as 50 percent of its raw material. It is an environmentally friendly packaging that aligns with the concept of carbon neutrality to balance greenhouse gas emissions and absorption.

• The Ministry of Industry and Trade announced the start date of the experiment on online trading of prescription drugs

  12 October 2021 GxPnews

  An experiment on online trading of prescription drugs will begin in the Russian Federation on January 1 next year, Denis Manturov, Russia’s Minister of Industry and Trade said at the Ecomference Rupost Retail Week International e-Commerce Forum.

• How an Effective Data Strategy can Transform Business Decisions and Improve Outcomes

  11 October 2021 Andrew Burkus / FiercePharma

  The life sciences industry has access to vast repositories of global patient data that can richly enhance how a brand can go to market in an intelligent and efficient manner. These real-world data (RWD) sets can be mined for detailed insights about the patient journey, treatment trends, greater understanding as to how healthcare professionals (HCPs) make decisions about patient care, the effects of payers and insurance companies, and myriad other factors.